Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 783 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

NCT00978055
View directory record Official record
Conditions
Healthy
Interventions
1: Liothyronine Sodium Tablets, 2: Cytomel® Tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2009 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

NCT00647660
View directory record Official record
Conditions
Healthy
Interventions
Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg, Corzide® Tablets 80 mg/5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

NCT00838630
View directory record Official record
Conditions
Healthy
Interventions
Cilostazol 100 mg tablets, Pletal® 100 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg

NCT00648557
View directory record Official record
Conditions
Healthy
Interventions
Levothyroxine Sodium Tablets 200 mg, Synthroid Tablets 200 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

NCT05089019
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

NCT01192139
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

NCT01518712
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 29, 2012 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Prilosec Bioequivalence Study in Healthy Volunteers

NCT01921920
View directory record Official record
Conditions
Bioequivalence, AUC, Cmax, Pharmacokinetics
Interventions
Omeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

NCT01101165
View directory record Official record
Conditions
Healthy
Interventions
Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 11, 2010 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects

NCT00772265
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin N, Novolin N
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefprozil 500 mg Tablets Under Fasting Conditions

NCT00840281
View directory record Official record
Conditions
Healthy
Interventions
Cefzil® 500 mg tablets, Cefprozil 500 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products

NCT01592019
View directory record Official record
Conditions
Bioequivalence
Interventions
Reference, Patch location thigh, batch 1, Test, Patch location thigh, batch 2, Reference, Patch location abdomen, batch 1, Test, Patch location abdomen, batch 2
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

NCT00897390
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 4 Interventional Results available

Clinical Study of Generic and Brand Bupropion in Depression

NCT02209597
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Bupropion XL 300
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg

NCT00649233
View directory record Official record
Conditions
Healthy
Interventions
Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg, Lopressor HCT® Tablets 100/50 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of APX001 High-load and Low-load Tablets

NCT05491733
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
APX001, APX001A
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

NCT01570907
View directory record Official record
Conditions
Treatment for Bipolar I Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional

Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer

NCT00100139
View directory record Official record
Conditions
Neoplasm
Interventions
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU), Paclitaxel for injection (Taxol)
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

NCT01454622
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

NCT00864500
View directory record Official record
Conditions
Healthy
Interventions
Clobetasol Propionate 0.05% lotion, single exposure, Clobex TM 0.05% Lotion, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

NCT02173392
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
6
States / cities
Glendale, California • Aventura, Florida • Saint Paul, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

NCT00865605
View directory record Official record
Conditions
Healthy
Interventions
Halobetasol Propionate 0.05% Ointment, single exposure, Ultravate® 0.05% ointment, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 24, 2026, 3:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fasting Conditions

NCT00864019
View directory record Official record
Conditions
Healthy
Interventions
Sertraline HCl 100 mg tablets, single dose, Zoloft® 100 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 24, 2026, 3:28 AM EDT